Shares of Gritstone Oncology Inc (NASDAQ:GRTS) hit a new 52-week high during trading on Thursday . The company traded as high as $30.41 and last traded at $31.08, with a volume of 2783 shares changing hands. The stock had previously closed at $30.23.

A number of analysts have recently commented on the company. Cowen assumed coverage on Gritstone Oncology in a report on Tuesday, October 23rd. They issued an “outperform” rating on the stock. Barclays assumed coverage on Gritstone Oncology in a report on Tuesday, October 23rd. They issued an “overweight” rating and a $25.00 price target on the stock. Goldman Sachs Group assumed coverage on Gritstone Oncology in a report on Tuesday, October 23rd. They issued a “neutral” rating and a $18.00 price target on the stock. Finally, BTIG Research initiated coverage on Gritstone Oncology in a report on Tuesday, October 23rd. They issued a “buy” rating and a $26.00 price target on the stock.

Gritstone Oncology (NASDAQ:GRTS) last released its earnings results on Wednesday, November 14th. The company reported ($7.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($6.97). The company had revenue of $0.10 million during the quarter.

In other Gritstone Oncology news, Director Nicholas Simon purchased 333,333 shares of the stock in a transaction on Friday, September 28th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of hedge funds and other institutional investors have recently made changes to their positions in GRTS. Riverhead Capital Management LLC acquired a new position in Gritstone Oncology during the third quarter worth approximately $141,000. Point72 Asset Management L.P. acquired a new position in Gritstone Oncology during the third quarter worth approximately $142,000. Partner Investment Management L.P. acquired a new position in Gritstone Oncology during the third quarter worth approximately $165,000. Pentwater Capital Management LP acquired a new position in Gritstone Oncology during the third quarter worth approximately $244,000. Finally, Alliancebernstein L.P. acquired a new position in Gritstone Oncology during the third quarter worth approximately $285,000. 43.52% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Gritstone Oncology (GRTS) Reaches New 1-Year High at $30.41” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/gritstone-oncology-grts-reaches-new-1-year-high-at-30-41/2665719.html.

Gritstone Oncology Company Profile (NASDAQ:GRTS)

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Featured Article: Relative Strength Index

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.